ITRM20040395A1 - Composizione comprendente statine e acidi grassi omega 3. - Google Patents

Composizione comprendente statine e acidi grassi omega 3.

Info

Publication number
ITRM20040395A1
ITRM20040395A1 IT000395A ITRM20040395A ITRM20040395A1 IT RM20040395 A1 ITRM20040395 A1 IT RM20040395A1 IT 000395 A IT000395 A IT 000395A IT RM20040395 A ITRM20040395 A IT RM20040395A IT RM20040395 A1 ITRM20040395 A1 IT RM20040395A1
Authority
IT
Italy
Prior art keywords
statines
fatty acids
composition including
acids omega
omega
Prior art date
Application number
IT000395A
Other languages
English (en)
Italian (it)
Inventor
Per Il Credito Sportivo Istituto
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000395A priority Critical patent/ITRM20040395A1/it
Publication of ITRM20040395A1 publication Critical patent/ITRM20040395A1/it
Priority to HK07111294.3A priority patent/HK1105871B/xx
Priority to NZ552396A priority patent/NZ552396A/en
Priority to PT57694861T priority patent/PT1773312E/pt
Priority to CN2005800258385A priority patent/CN1993119B/zh
Priority to KR1020077004538A priority patent/KR101355122B1/ko
Priority to PCT/IT2005/000414 priority patent/WO2006013602A1/en
Priority to BRPI0514026-9A priority patent/BRPI0514026A/pt
Priority to CA2573000A priority patent/CA2573000C/en
Priority to DK05769486.1T priority patent/DK1773312T3/da
Priority to ES05769486.1T priority patent/ES2481169T3/es
Priority to US11/632,953 priority patent/US8853229B2/en
Priority to SI200531865T priority patent/SI1773312T1/sl
Priority to PL05769486T priority patent/PL1773312T3/pl
Priority to EP05769486.1A priority patent/EP1773312B1/en
Priority to AU2005268402A priority patent/AU2005268402B2/en
Priority to MX2007001009A priority patent/MX2007001009A/es
Priority to EA200700240A priority patent/EA014444B1/ru
Priority to JP2007524466A priority patent/JP5103179B2/ja
Priority to IL180602A priority patent/IL180602A/en
Priority to ZA200701816A priority patent/ZA200701816B/en
Priority to CY20141100583T priority patent/CY1115416T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000395A 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3. ITRM20040395A1 (it)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.
JP2007524466A JP5103179B2 (ja) 2004-08-03 2005-07-19 スタチンおよびオメガ−3脂肪酸を含む組成物
ES05769486.1T ES2481169T3 (es) 2004-08-03 2005-07-19 Composición que contiene estatinas y ácidos grasos omega-3
SI200531865T SI1773312T1 (sl) 2004-08-03 2005-07-19 Sestavek, ki vsebuje statine in maščobne kisline omega-3
PT57694861T PT1773312E (pt) 2004-08-03 2005-07-19 Composição contendo estatinas e ácidos graxos ómega-3
CN2005800258385A CN1993119B (zh) 2004-08-03 2005-07-19 含他汀类药物和ω-3脂肪酸的组合物
KR1020077004538A KR101355122B1 (ko) 2004-08-03 2005-07-19 스타틴 및 오메가 3 지방산 함유 조성물
PCT/IT2005/000414 WO2006013602A1 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
BRPI0514026-9A BRPI0514026A (pt) 2004-08-03 2005-07-19 composição contendo estatinas e ácidos graxos Èmega-3
CA2573000A CA2573000C (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
DK05769486.1T DK1773312T3 (da) 2004-08-03 2005-07-19 Sammensætning omfattende statiner og omega-3-fedtsyrer
HK07111294.3A HK1105871B (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
US11/632,953 US8853229B2 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
NZ552396A NZ552396A (en) 2004-08-03 2005-07-19 Composition containing simvastatin, coenzyme Q10, resveratrol, pantethine and omega-3 fatty acids
PL05769486T PL1773312T3 (pl) 2004-08-03 2005-07-19 Kompozycja zawierająca statyny i kwasy tłuszczowe omega-3
EP05769486.1A EP1773312B1 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
AU2005268402A AU2005268402B2 (en) 2004-08-03 2005-07-19 Composition containing statins and omega-3 fatty acids
MX2007001009A MX2007001009A (es) 2004-08-03 2005-07-19 Composicion que contiene estatinas y acidos grasos omega-3.
EA200700240A EA014444B1 (ru) 2004-08-03 2005-07-19 Композиция, содержащая статины и омега-3 жирные кислоты
IL180602A IL180602A (en) 2004-08-03 2007-01-08 An ingredient containing statins and omega-3 fatty acids
ZA200701816A ZA200701816B (en) 2004-08-03 2007-03-01 Composition containing statins and omega -3 fatty acids
CY20141100583T CY1115416T1 (el) 2004-08-03 2014-07-16 Συνθεση που περιεχει στατινες και ωμεγα-3 λιπαρα οξεα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.

Publications (1)

Publication Number Publication Date
ITRM20040395A1 true ITRM20040395A1 (it) 2004-11-03

Family

ID=35124288

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000395A ITRM20040395A1 (it) 2004-08-03 2004-08-03 Composizione comprendente statine e acidi grassi omega 3.

Country Status (21)

Country Link
US (1) US8853229B2 (https=)
EP (1) EP1773312B1 (https=)
JP (1) JP5103179B2 (https=)
KR (1) KR101355122B1 (https=)
CN (1) CN1993119B (https=)
AU (1) AU2005268402B2 (https=)
BR (1) BRPI0514026A (https=)
CA (1) CA2573000C (https=)
CY (1) CY1115416T1 (https=)
DK (1) DK1773312T3 (https=)
EA (1) EA014444B1 (https=)
ES (1) ES2481169T3 (https=)
IL (1) IL180602A (https=)
IT (1) ITRM20040395A1 (https=)
MX (1) MX2007001009A (https=)
NZ (1) NZ552396A (https=)
PL (1) PL1773312T3 (https=)
PT (1) PT1773312E (https=)
SI (1) SI1773312T1 (https=)
WO (1) WO2006013602A1 (https=)
ZA (1) ZA200701816B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509154A (ja) 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
KR20070108945A (ko) * 2005-03-08 2007-11-13 릴라이언트 파마슈티컬스 인코퍼레이티드 스타틴과 오메가-3 지방산 및 그 조합물을 이용한 치료
CN101365431A (zh) * 2005-10-14 2009-02-11 帝斯曼知识产权资产管理有限公司 包含白藜芦醇的营养药物组合物的新颖用途
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20080085911A1 (en) 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2539921C2 (ru) * 2009-06-12 2015-01-27 Каланус Ас Композиция из жира веслоногих ракообразных, препарат, содержащий эту композицию, включающую жир, ее применение для снижения накопления висцерального жира, улучшения толерантности к глюкозе, предотвращения или лечения заболеваний и расстройств, связанных с ожирением
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
MX2012006993A (es) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Composicion de combinacion util para el tratamiento de enfermedades cardiovasculares.
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
RU2543539C2 (ru) 2010-12-20 2015-03-10 Хилл'С Пет Ньютришн, Инк. Кормовые композиции для домашних животных, вызывающие чувство сытости
AU2015201809B2 (en) * 2010-12-20 2016-09-29 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
JP6359517B2 (ja) * 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−3脂肪酸エステル組成物
WO2013149258A2 (en) * 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions and methods for treating or preventing metabolic syndrome disorders
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2015003246A1 (en) * 2013-07-09 2015-01-15 Mcmaster University Combination of a statin with an inflammasome inhibitor
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
RU2554806C1 (ru) * 2014-07-29 2015-06-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Способ коррекции повышенного уровня тревоги и депрессии у пациентов с артериальной гипертонией на фоне сахарного диабета 2 типа
CN104922160A (zh) * 2015-05-22 2015-09-23 舟山三合生物科技有限公司 他汀与Omega-3脂肪酸和辅酶Q10复配的组合物及其应用
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
ITUA20162575A1 (it) 2016-04-13 2017-10-13 S&R Farm S P A Composizione farmaceutica o nutraceutica per l’uso nel trattamento della sindrome dell’ovaio policistico o di malattie o disturbi correlati ad essa
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US12171728B2 (en) 2018-04-16 2024-12-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1055638C (zh) * 1995-07-14 2000-08-23 李江 富硒虫草口服液及其制备方法
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US20030228393A1 (en) * 2002-05-31 2003-12-11 Zhao Iris Ginron Multi-phase food & beverage
CN1061259C (zh) * 1998-11-24 2001-01-31 彭素萍 藜蒿中生物活性物质的富集物及用途
CA2427618A1 (en) 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
US20050002992A1 (en) * 2003-06-17 2005-01-06 Mccleary Edward Larry Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20020182585A1 (en) 2001-01-10 2002-12-05 George Kindness Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20040018248A1 (en) * 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US6855353B2 (en) * 2002-03-08 2005-02-15 Yaguang Liu Method for producing antioxidant and prevention of cancer
EP1536698A1 (en) * 2002-08-23 2005-06-08 DSM IP Assets B.V. Novel nutraceutical compositions comprising biotin
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
EP1558244A2 (en) 2002-11-07 2005-08-03 DSM IP Assets B.V. Novel nutraceutical compositions comprising epigallocatechin gallate

Also Published As

Publication number Publication date
BRPI0514026A (pt) 2008-05-27
PT1773312E (pt) 2014-07-25
CN1993119A (zh) 2007-07-04
AU2005268402A1 (en) 2006-02-09
EP1773312B1 (en) 2014-05-07
HK1105871A1 (en) 2008-02-29
EA200700240A1 (ru) 2007-06-29
US8853229B2 (en) 2014-10-07
CA2573000C (en) 2014-03-11
ZA200701816B (en) 2008-07-30
EA014444B1 (ru) 2010-12-30
PL1773312T3 (pl) 2014-09-30
CY1115416T1 (el) 2017-01-04
CA2573000A1 (en) 2006-02-09
MX2007001009A (es) 2007-04-16
DK1773312T3 (da) 2014-07-21
IL180602A0 (en) 2008-03-20
IL180602A (en) 2015-06-30
NZ552396A (en) 2009-08-28
ES2481169T3 (es) 2014-07-29
KR20070058460A (ko) 2007-06-08
EP1773312A1 (en) 2007-04-18
JP2008509132A (ja) 2008-03-27
AU2005268402B2 (en) 2010-08-26
JP5103179B2 (ja) 2012-12-19
SI1773312T1 (sl) 2014-08-29
CN1993119B (zh) 2011-04-06
WO2006013602A1 (en) 2006-02-09
US20080089876A1 (en) 2008-04-17
KR101355122B1 (ko) 2014-02-04

Similar Documents

Publication Publication Date Title
ITRM20040395A1 (it) Composizione comprendente statine e acidi grassi omega 3.
ATE523489T1 (de) 3&#39;-alkoxy spirocyclische tetram- und tetronsäuren
DK1663936T3 (da) Biaryloxymethylaren-carboxylsyrer
NO20054957D0 (no) Subtituerte karboksylsyrer
EP1861087A4 (en) TREATMENT WITH STATINE AND OMEGA-3-FATTY ACID AS A COMBINATION PRODUCT THEREOF
FI20031301L (fi) Esteröintimenetelmä
IL210233A0 (en) Omega 3 fatty acid formulations
ATE517887T1 (de) Neue 2-pyridincarbonsäureamidderivate
EE200300030A (et) 4-jodofenüülaminobenshüdroksaamhapete oksügeenitud estrid
SM200600001S1 (it) Modello ornamentale multiplo costituito da 5 seriedi caratteri tipografici
NO20054747D0 (no) Fosforsyreester-demulgerende sammensetning
ATE439362T1 (de) Ester in position 20 von camptothecinen
ATE432918T1 (de) Verfahren zur herstellung von cpla 2-inhibitoren
DE60143052D1 (de) Lipid vom carbonsäuretyp
DE502004001633D1 (de) Verfahren zur Herstellung von Anilinboronsäuren und ihren Derivaten
ATE459726T1 (de) Verfahren und produkte
DE502004010072D1 (de) Fettdichter textildarm
DE602006014845D1 (de) Zweistufiges verfahren zur herstellung von fettsäuren
FR2905066B1 (fr) Procede de peeling a base de tensioactifs et d&#39;acides
ITMI20020750A1 (it) Acidi grassi essenziali nel trattamento di cardiopatie
FI20041240A0 (fi) Menetelmä rasvahappojen esteröimiseksi
ITTO20060063A1 (it) Corredo per l&#39;amplificazione di acidi nucleici.
DE50114934D1 (de) Verfahren zur Ermittlung der Nettofallhöhe von Turbinen
NO20022578D0 (no) Fosfolipider inneholdende omega-3 fettsyrer
ITMI20020825A1 (it) Ottenimento di esteri alchilici da trigliceridi di origine animale o vegetale in presenza di acidi grassi liberi